<?xml version="1.0" encoding="UTF-8"?>
<p>All SHARED‐2 participants completed the study and were evaluable for the primary efficacy endpoint. A total of 52 participants (87%; 95% confidence interval [CI]: 80, 96; Fig. 
 <xref rid="hep41482-fig-0002" ref-type="fig">2</xref>) achieved SVR12, similar to the SVR12 rate in the participants who had routine on‐treatment laboratory monitoring in SHARED‐1 (209 of 240; 87%; 95% CI: 82, 91).
</p>
